Newland Pharmaceutical Co., Ltd. (SHE:301277)
China flag China · Delayed Price · Currency is CNY
12.81
+0.13 (1.03%)
At close: Feb 27, 2026

Newland Pharmaceutical Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20
5,0233,8734,1633,850--
Market Cap Growth
30.05%-6.96%8.12%---
Enterprise Value
4,3133,0723,3783,956--
Last Close Price
12.819.6410.199.28--
PE Ratio
40.5922.3126.1929.10--
PS Ratio
7.495.336.396.14--
PB Ratio
3.302.512.872.83--
P/TBV Ratio
3.412.572.952.92--
P/FCF Ratio
304.44242.5025.55452.81--
P/OCF Ratio
37.1530.5616.0446.47--
EV/Sales Ratio
6.434.235.196.31--
EV/EBITDA Ratio
25.6314.2217.7223.63--
EV/EBIT Ratio
34.2216.9820.8727.22--
EV/FCF Ratio
261.44192.3320.73465.21--
Debt / Equity Ratio
0.000.000.000.000.310.35
Debt / EBITDA Ratio
0.040.010.010.030.800.69
Debt / FCF Ratio
0.370.190.020.675.343.57
Net Debt / Equity Ratio
-0.47-0.52-0.59-0.550.210.24
Net Debt / EBITDA Ratio
-4.28-3.72-4.49-4.460.530.46
Net Debt / FCF Ratio
-43.02-50.32-5.26-87.833.532.38
Asset Turnover
0.390.420.410.570.860.90
Inventory Turnover
7.1011.509.306.124.815.81
Quick Ratio
5.735.267.897.141.421.22
Current Ratio
6.305.518.297.611.821.51
Return on Equity (ROE)
8.07%11.56%11.19%14.92%31.91%46.93%
Return on Assets (ROA)
4.52%6.61%6.44%8.25%14.32%18.59%
Return on Invested Capital (ROIC)
13.21%23.81%23.31%24.30%27.06%41.41%
Return on Capital Employed (ROCE)
8.00%11.30%11.00%10.50%30.50%41.50%
Earnings Yield
2.46%4.48%3.82%3.44%--
FCF Yield
0.33%0.41%3.91%0.22%--
Dividend Yield
2.25%2.96%2.00%1.83%--
Payout Ratio
90.55%46.08%41.94%5.12%31.92%45.98%
Buyback Yield / Dilution
-0.39%-0.39%-29.52%-2.59%-0.64%-0.34%
Total Shareholder Return
1.85%2.57%-27.51%-0.75%-0.64%-0.34%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.